CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

(MedPage Today) — Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high rate of non-relapse mortality in patients with multiple myeloma, according to a retrospective study…

Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/119503

Author :

Publish date : 2026-01-20 21:07:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

Study: Helping Lupus Patients With Money Issues Improves Their Health

Parent-Led Intervention Started in NICU Boosted Executive Function at School Age

Related Posts

Ixchiq Vaccine Pulled From U.S. Market Amid Safety Concerns

Parent-Led Intervention Started in NICU Boosted Executive Function at School Age

Study: Helping Lupus Patients With Money Issues Improves Their Health

After My Breast Cancer Diagnosis, My Practice Became a Lab for Change

Medicare Paying Billions More for Medicare Advantage vs Traditional Enrollees

Coming Radiotracer Shortage; Dedicated Cardiometabolic Training; New PFA Catheter

Ixchiq Vaccine Pulled From U.S. Market Amid Safety Concerns

Parent-Led Intervention Started in NICU Boosted Executive Function at School Age

CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

Study: Helping Lupus Patients With Money Issues Improves Their Health

After My Breast Cancer Diagnosis, My Practice Became a Lab for Change

Medicare Paying Billions More for Medicare Advantage vs Traditional Enrollees

Coming Radiotracer Shortage; Dedicated Cardiometabolic Training; New PFA Catheter

Discussing Personalized Treatment Options in Breast Cancer

Categories

Archives